Europe's Pharma Chiefs Beg Governments for FDA-Speed Trials — Confirming a Permanent Moat for US Drug Stocks

On September 22, 2026, the chairs of nine European drugmakers — AstraZeneca, GSK, Novo Nordisk, Novartis, Roche, Sanofi, Boehringer Ingelheim, Chiesi and Ipsen — published an open letter on their company websites calling on the European Union and member states to lift pharmaceutical investment. The demands were unusually specific for a sector that usually lobbies behind closed doors: faster clinical trials, beefed-up government spending on medicines, fiscal flexibility on healthcare budgets, and stronger IP protections.

What makes this more than routine lobbying is that it is the first time Europe's largest pharma employers have publicly admitted, on the record, that the continent is structurally losing the global R&D race. The letter doesn't name the FDA, but the numbers it implicitly relies on — laid out in the European Federation of Pharmaceutical Industries and Associations' (EFPIA) July 2, 2026 competitiveness report — do. The briefing frames the gap as a manageable policy choice. The data frames it as a moat.

The European pharma footprint in global drug R&D has been compressed on every axis that matters for investors. EFPIA's competitiveness analysis, benchmarked against the US, China, the UK and Switzerland, leaves little room for spin.

The single sharpest number in EFPIA's report is the approval-time gap: a new drug takes a median of 356 days to clear the FDA, 390 days in China, and 430 days in the EU. Seventy-four extra days of review may sound modest, but multiplied across a portfolio and discounted against patent life, it compresses peak sales windows and pulls payback periods forward.

The expedited-pathway line is the most damning. EU regulators used fast-track review for 20% of new active substances in 2015 — and for exactly 0% in 2024. The US used expedited review for 53% of its new drugs in 2024; China, 35%. The combination of a slower clock and a near-total absence of accelerated lanes means a US-launched product can reach peak years of sales before the EU label is finalized, then faces a second squeeze from EU price negotiations that the chairs say leave roughly 40% of approved therapies on the shelf.

What turned a policy complaint into a market event was the timing. The September 22 letter landed two weeks after the most bruising stretch of European pipeline news in years — three failures in two months, all hitting drugmakers that signed the open letter or share the same regulatory exposure.

Stripped of personalities, the pattern is what the lobby letter is really about. Two of the three companies that just took the worst hits (AstraZeneca and Novartis) signed the September 22 letter. The third (BioNTech) is a German-headquartered mRNA platform whose biggest near-term commercial opportunities still run through the US regulatory pathway. None of the three failures was a regulatory-speed issue — but each illustrates how EU-headquartered R&D is being repriced in a market that already discounts European pipelines for slower approvals and weaker launch uptake.

Read straight, the September 22 letter is a competitive admission rather than a competitive threat. The European industry is conceding — in writing, with the EFPIA data behind it — that the FDA's regulatory speed is a structural feature of the US market that European policymakers have not been able to replicate and now admit they cannot match in the near term. For investors, that has three concrete implications.

One: US pharma premium multiples have a justification the bears have been calling a mirage. Eli Lilly trades at 39x trailing earnings on $79.7B of TTM revenue, with Q2 2026 revenue up 48% year-over-year on Mounjaro ($9.9B, +91%) and Zepbound ($4.93B), per Lilly's August 5, 2026 release. That multiple looks rich in isolation. Anchored against a 430-day EU clock and a 0% EU expedited-review rate, it looks like the cost of being on the right side of the regulatory divide.

Two: European pharma's structural discount is now policy-blessed, not transitory. AstraZeneca trades at 24.9x trailing earnings, Novartis at 21.2x and Sanofi similarly below US peers — despite Q2 2026 oncology revenue at AstraZeneca up 15% to $14.1B in H1 (AstraZeneca H1 2026 release, Jul 27, 2026). The discount used to be blamed on idiosyncratic pipeline risk; it now has a self-confessed policy floor under it.

Three: China's competitive threat is the variable EU reform cannot solve. EFPIA reports China's share of new active substance origin climbed from 4 (2018) to 28 (2024), while the EU's slipped. BeiGene — now BeOne Medicines — captured an FDA accelerated approval for Brukinsa in follicular lymphoma and reported Q2 2026 revenue up ~30% with US-led momentum, per the company's investor materials and the BeiGene Q2 2026 earnings call. China is not just a low-cost producer anymore; it is a faster, increasingly US-grade regulator with a pipeline that the EU cannot out-spend or out-speed.